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Abstract
Papillomaviruses use rare codons relative to their hosts. Recent studies have demonstrated that synonymous codon
changes in viral genes can lead to increased protein production when the codons are matched to those of cells in which the
protein is being expressed. We theorized that the immunogenicity of the virus would be enhanced by matching codons of
selected viral genes to those of the host. We report here that synonymous codon changes in the E7 oncogene are tolerated
in the context of the cottontail rabbit papillomavirus (CRPV) genome. Papilloma growth rates differ depending upon the
changes made indicating that synonymous codons are not necessarily neutral. Immunization with wild type E7 DNA yielded
significant protection from subsequent challenge by both wild type and codon-modified genomes. The reduction in growth
was most dramatic with the genome containing the greatest number of synonymous codon changes.
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Introduction
Papillomaviruses are double-stranded DNA tumor viruses of
about 8 kb. There are more than 100 human papillomavirus
types, some specific for mucosal tissues and others for cutaneous
sites. A subset of the viruses is associated with cancers, in particular
cancer of the cervix.
Papillomaviruses use rare codons relative to their hosts [1,2]. It
has been argued that this is an evolutionary adaptation, which
allows the virus to escape immune surveillance [3]. Nonetheless,
the reasons for codon bias are poorly understood. There is a
growing recognition that synonymous codon usage is not always
neutral [4–6]. Many reasons have been posited for codon choice.
Among them are: 1. Control of translation rate and gene
expression [7,8]. 2. Control of protein folding [9–11]. 3.
Nucleosome positioning [12]. 4. Tissue specificity requirements
[13–15]. 5. RNA stability, secondary structure and degradation
parameters [16–20] 6. Selection for translational efficiency [21]
and 7. Provision for splicing [22].
There are very few models to study the impact of synonymous
codon changes. Carlini [23] changed common leucine codons to
uncommon counterparts in the alcohol dehydrogenase gene of
Drosophila and found decreasing tolerance to alcohol with
increasing numbers of uncommon codons. Komar et. al. [10]
replaced 16 rare codons in the chlorampenicol acetyltransferase
(CAT) gene of E. coli with common codons and found accelerated
protein synthesis but reduced specific activity. The authors
interpreted their data to suggest that the accelerated rate of protein
production resulted in partial misfolding of the protein and hence,
reduced activity. Poliovirus capsid gene deoptimization, reported in
two recent studies, led to attenuation of the virus [24,25]. While the
two groups did not agree on the mechanisms for the attenuation,
their results are in agreement and show the power of synonymous
codon change to produce phenotypic changes in the virus.
A major focus of this laboratory is the immunology of
papillomaviruses. Our previous studies as well as those of others
have shown that vaccination of the domestic rabbit with the four
earlyproteinsofthe cottontailrabbitpapillomavirus(CRPV) (E1,E2,
E6 and E7) can provide complete protection from subsequent viral
challenge [26,27]. We have also shown that E7 does not appear to
participate in this protection although vaccination with E7 does
delay progression to cancer [28]. E7 is one of the oncogenes of the
papillomavirus. Because of its continuous presence in progressive
tumors, E7 has been tested as an immunotherapeutic target in
animal models and clinical trials [29–32]. We have recently begun
studies with this model to examine host-virus interactions following
synonymous codon alterations in several viral genes. In our initial
study reported here, we hypothesized that codon ‘‘optimization’’ of
the E7 gene in the context of the CRPV genome would result in
increased protein production and thus enhanced immunogenicity.
To investigate this question, we constructed E7 genes with 8, 14, 18
and 22 synonymous codon changes (E7/8, E7/14 etc.). In vitro
studies with these genes confirmed that more E7 protein was
produced by E7/18 and E7/22 than by E7/wild type(wt), E7/8 or
E7/14. The increased protein production could have resulted from
the increased mRNA (E7/22) and/or the more stable mRNA (E7/
18 and E7/22) that was demonstrated by QRT-PCR analysis. We
placed these modified E7 genes into the CRPV genome in place of
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e2947the wild type E7 gene. These codon-modified genomes were tested
for functional growth and for immunogenicity following E7
vaccination. We found that all genomes were functional and all
responded by growth reduction upon immunization with wild type
E7 DNA vaccine. CRPV containing 22 changes in E7 showed the
largest growth retardation in vaccinated animals. This work
demonstrates the concept that codon bias can play a role in the
immune response to an infectious organism and supports the
hypothesis that papillomaviruses have evolved their codon usage to
reduce exposure to immune detection. Our in vivo model will be a
useful tool to study further questions surrounding papillomavirus
codon bias in the papillomavirus life cycle.
Results
Protein production, as determined by
immunoprecipitation, increased with increasing numbers
of optimized codons in E7
Codon changes within the CRPV E7 gene were made to match
common codon usage of mammalian genes. A series of 4 E7 genes
was constructed to give 8, 14, 18 and 22 sequential codon changes
(Fig 1). The latter 3 constructs were built upon the changes already
incorporated into the previous construct. This strategy was
designed to generate a panel of intermediate reagents that could
be used to test the effects of codon changes and also to detect
Figure 1. Location of codon changes in H. CRPV E7. Each of the codon changes introduced into H. CRPV E7 is noted. The changes were
cumulative. For example E7/14 contains all the changes in E7/8 plus 6 unique to itself; E7/18 contains the 14 in E7/14 plus 4 unique to itself; E7/22
contains all of the changes noted. Upper lines represent wild type E7 sequence and lower lines, the codon-modified sequences with changes noted in
bold. Single letter notations are used for the amino acids. The numbers above selected amino acids identify the genome containing the codon
modification of that amino acid.
doi:10.1371/journal.pone.0002947.g001
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codons were changed in a single and final E7 construct. The E7
protein produced in transiently transfected cells was immunopre-
cipitated using a monoclonal antibody to CRPV E7 (E7-1)
generated in house. Protein was detected in the positive control
and in cells transfected with E7/18 and E7/22 but not in cells
transfected with wild type E7 or E7/8 and E7/14 (Fig 2). These in
vitro results are consistent with the hypothesis that increases in
‘‘optimal’’ codons may favor increased protein production and
also consistent with the work of Cid-Arregui, et. al. with HPV 16
E7 [33]. In addition, Samorski et. al. [34] report similar findings
with HPV 16 E6.
Increased E7 protein production with increasing
numbers of codon ‘‘optimizations’’ was confirmed by
FSCAN analysis
E7 expression in cell lines transfected with wild type E7, E7/14,
E7/18, and E7/22 was also tested by FSCAN flow cytometry.
Consistent with the results from the immunoprecipitation study,
statistically significant increase in protein expression with increas-
ing numbers of codon changes was found (Fig 3, P,0.05, unpaired
student t test). The increased protein production appeared to
suppress the expression of EGFP significantly when EGFP was co-
transfected at the same time as a control for transfection efficiency
(Fig 4, P,0.05, unpaired student t test).
E7 Messenger RNA levels were elevated in transiently but
not in stably transfected cells
To investigate whether E7 protein levels correlated with RNA
levels, Northern blot analysis was performed. RNA extracted from
cell lines transiently transfected with expression constructs of the
various optimized E7 genes showed a somewhat elevated expression
over wild type inthe two analyses conducted (Fig 5 is representative).
E7/8 showed the greatest elevation in both studies undertaken.
Northern analysis on RNA from stably transfected cell lines,
however, showed very little message. Whereas control b-actin
Figure 2. Immunoprecipitation of E7 proteins. Protein from transiently transfected cells was immunoprecipitated, run out on a PAGE gel and
detected using a monoclonal antibody to E7, MAb E7-1. Increasing amounts of protein were detected with increasing numbers of codon changes.
doi:10.1371/journal.pone.0002947.g002
Figure 3. FSCAN analysis of cells transfected with E7 expres-
sion constructs. Expression of E7 protein was detected in immortal-
ized rabbit cells transfected with expression constructs of the E7 genes
and subjected to FSCAN analysis. All analyses were done in duplicate.
E7/18 and E7/22 showed the highest expression levels.( p,0.05,
unpaired student t test), when compared to the control.
doi:10.1371/journal.pone.0002947.g003
Figure 4. Analysis of expression of EGFP, used as a control for
transfection efficiency. Expression of EGFP was detected in all cells
cotransfected with E7 genes and an EGFP expression construct. All
transfections were done in duplicate. The amount of protein expressed
declined with increasing numbers of optimized codons in the E7 genes
suggesting down regulation due to expression of E7 (p,0.05, unpaired
student t test).
doi:10.1371/journal.pone.0002947.g004
Synonymous Codon Changes in E7
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necessary to detect the very weak E7 signals (data not shown). We
conclude that there is selection pressure in cells containing E7 DNA
such that stable lines express a limited amount of E7 protein.
However, in transiently transfected cells and prior to integration, the
cells do produce E7 message which appears to be elevated in codon-
optimized genes, especially E7/8. Similar findings were reported by
Cid-Arregui, et al. [33].
Quantitative RT- PCR analysis on mRNA isolated from
transiently transfected cells treated with Actinomycin D
at different time points showed elevated message for E7/
22 and more stable message for E7/18 and E7/22
Quantitative RT- PCR( QRT-PCR) is a powerful tool for the
quantitative analysis of transcripts. We chose to follow up the
Northern analysis above with the far more sensitive quantitative
RT-PCR analysis and to combine this with an Actinomycin D
assay in order to evaluate stability of the messages over time. In
this study we looked at wild type E7 and E7/14, E7/18, and E7/
22. E7/8 was not included due to assay constraints. The TBP
(TATA binding protein) was used as internal standard to make use
of primers and probes available in the laboratory. All codon-
modified genes utilized the same set of E7 primers and probe; E7/
wild type amplification required a slightly modified set. In this
analysis, which was conducted in duplicate, we found that TBP
was not stable over time; thus each analysis included a standard
curve to allow for quantitation. We found that E7/wild type, E7/
14 and E7/18 messages were all present at about the same level
whereas E7/22 message was four fold higher (Fig 6). Furthermore,
we determined that message stability increased with increasing
numbers of codon changes (Fig 7). The relative mRNA values
were not entirely consistent with those obtained by Northern
analysis above. The differences may be attributable to different
conditions in the respective assays and/or to the quantitation
methods. The Northern analysis was quantitated by densitometry,
which is inherently less reliable than the QRT-PCR analysis, in
part due to potential saturation of signals. Of note is the fact that
E7/8, whose message was most highly elevated in the Northern
analysis, was not able to be included in the QRT-PCR analysis.
This will need to be addressed in future experiments.
RNA extracted from papillomas generated by codon-
optimized genomes did not show elevated message
Northern blot analysis was also conducted on RNA extracted
from selected papillomas generated by both wild type and codon-
optimized genomes. No apparent difference in E7 RNA level was
found among these samples suggesting that codon optimization
may not significantly influence E7 message production in the
intact host (data not shown). Message and protein production are
not always correlated and so we cannot conclude that the failure to
detect differences in RNA quantity in vivo implies that there are no
differences in protein production.
CRPV genomes, containing E7 with codon optimizations,
were functional and phenotypes were different
All genomes containing E7 optimizations were tested in New
Zealand White (NZW) outbred rabbits using our DNA infectivity
assay. All constructs were able to induce papillomas in these
animals at high efficiency. Papilloma growth occurred at wild type
rate for genomes containing E7/8 and E7/14, at an accelerated
rate for the genome containing E7/18, and at a reduced rate for
the genome containing E7/22 (Fig 8). There was a highly
significant difference between the growth rates of E7/18 and E7/
22 genomes (p,0.001, unpaired student t test) and a moderately
significant difference between E7/18 and wild type at later time
points (p,0.03, unpaired student t test; Fig 8). There was a
significant difference in growth rates at most time points between
E7/wild type and E7/22 ( p,0.02). These results demonstrate that
codon changes in the viral DNA are not necessarily neutral.
Codon-optimized changes were maintained in papilloma
DNA extracted from tumors
Genomic DNA was extracted from papillomas initiated with
different codon-optimized constructs and PCR was performed to
Figure 5. Northern blot analysis of cells transiently transfected with E7 expression constructs. RNA from transiently transfected cells was
blotted to Hybond N
+ membrane and probed for E7 message using a mixture of all E7 genes for the probe. Message was standardized to beta actin
control. Elevated E7 RNA signals were obtained for all codon-modified genes; E7/8 gave the highest signal.
doi:10.1371/journal.pone.0002947.g005
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investigated, the changes that had been introduced were
maintained in the replicated DNA (data not shown).
E7 DNA immunization resulted in a statistically significant
reduction in the growth of papillomas induced by
codon-optimized constructs
An immunization experiment was undertaken to explore the
response of codon-modified genomes to E7 DNA immunization.
Following a series of four gene gun immunizations with either wild
type E7 plasmid, or vector only, six animals per group were
challenged at two sites each with wild type CRPV DNA and with
each of the codon-optimized DNAs. Papilloma growth was
monitored for a period of two months. Complete protection was
seen for the E7 immunogen in one out of six rabbits. Volume of all
E7/8, E7/14 and E7/18 papillomas in the E7 immunogen group
was reduced by 30–50% when compared to those in the vector
immunization group, whereas volume of E7/22 papillomas was
reduced by 75%. (Fig 9, Table 1). These data support the
possibility that E7/22 is more immunogenic because the codon
optimizations present allow for the production of more protein.
Discussion
Papillomaviruses show significant bias in their codon usage with
a preference for AT3 vs. CG3 [40]. In an effort to investigate the
significance of this bias, and in acknowledgement of recent work,
which has shown increased protein production in vitro using codon-
optimized genes [2,41,42], we used our rabbit/CRPV DNA
infectivity model to allow us to begin to study synonymous codon
usage via alterations in the CRPV genome. We postulated that
Figure 6. Quantitative RT PCR analysis on total RNA from cells transiently transfected with wild type E7 or codon-modified E7
expression constructs demonstrated that E7/22 message was present at about four times the numbers of copies of the other genes.
RNA was isolated from transiently transfected cells and subjected to QRT- PCR. Standard curves were run with each reaction and quantitation of
message was done using these curves. E7/22 message was present at levels four fold higher than the other genes.
doi:10.1371/journal.pone.0002947.g006
Figure 7. An Actinomycin D time course demonstrated that message stability increased with increasing numbers of codon changes.
RNA was isolated from transiently transfected cells at different time points from 0 to six hours post treatment. RNA stability increased with increasing
numbers of codon changes.
doi:10.1371/journal.pone.0002947.g007
Synonymous Codon Changes in E7
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increased protein production and that this change could be
assessed immunologically.
The CRPV model is the only animal model in which the entire
life cycle of a papillomavirus from initiation of infection to
malignant progression can be studied [27,28,39]. The model has
the advantage that viral DNAs are infectious and thus mutants can
be made and evaluated without the need to produce infectious
virions. Synonymous codon mutants of the oncoprotein E7 were
developed to investigate the immunological response of genomes
containing these modifications. We chose the E7 protein for our
target as our earlier work had shown that the wild type protein was
poorly immunogenic [28]. Codon modifications of HPV16 E7
have been shown to enhance cytotoxic T cell Lymphocyte ( CTL)
induction and antitumor activity[32]. We hypothesized that
increasing numbers of ‘‘optimizations’’ of CRPV E7 within the
CRPV genome would lead to increased protein production and
that this would be detected as an improved response to
immunization. This approach is unique in that the infectious
agent was codon-modified rather than the immunogen, as is
typically done.
We have shown in this study, using an in vitro assay, that
increasing numbers of optimizations did, in fact, lead to increased
protein production. However, in situ quantitation of E7 content in
papillomas is more difficult and we do not yet have definitive proof
that this also occurred in vivo. We have shown, for example, that
significant protection was achieved when wild type E7 immuni-
zation was followed by challenge with both wild type and codon-
modified genomes on the same animal. In our previous work, no
protection was found with wild type E7 immunization when
animals were subsequently challenged with wild type CRPV [28].
We interpret these results to suggest that one or more of the
codon-modified genomes produced enough E7 protein to be
detected by the immune system and that this stimulated a systemic
response that was manifested as a reduction in size of papillomas
initiated by all genomes including wild type.
We created four mutant viral strains containing 8, 14, 18, or 22
synonymous changes in E7. Changes were made at random to
codons for a number of amino acids including isoleucine (2),
threonine (3), proline (1), leucine (7), serine (2), glutamine (2), and
alanine (3). CG3 for wild type H. CRPV E7 is 44%, whereas CG3
for our most highly optimized genome, E7/22, is 65%. Thus, the
changes yielded E7 genes whose codons more closely approxi-
mated those of mammals as reported by Zhou et. al. [2]. We
compared the ubiquitously expressed MHC class I rabbit gene
sequence (Genbank K024441) with a BLAST search of human
genes and found greater than 90% homology between human
MHC class I precursors and the rabbit gene. Codon usage is
nearly identical. This lends validity to our appropriation of human
codon usage in the absence of sufficient information on the rabbit
genome. We should note that we made codon changes based on
the most common usage on average in the human genome. We
acknowledge that we do not know if these codons are truly
‘‘optimal’’, that is selected for maximal translation in mammals.
The understanding of codon usage, especially in mammalian
systems, is still incomplete. We can simply say at this point that we
replaced codons of CRPV E7 , codons known to be uncommon in
Figure 8. Sizes of papillomas differed among the different
genotypes. Growth curves of papillomas following infection with wild
type and codon-optimized genomes. E7/8 and E7/14 papillomas grew
at about wild type rate; E7/18 papillomas grew statistically faster than
E7/22 papillomas (P,0. 001, unpaired student’s t test); E7/18 papillomas
grew statistically faster at later time points than wild type papillomas
(P,0.03 unpaired student’s t test).
doi:10.1371/journal.pone.0002947.g008
Figure 9. Results of vaccination study. Animals were vaccinated
with either wild type E7 (q,n,%) or empty vector (N,m,&) and were
then challenged with each of the CRPV genomes including wild type.
Vaccination resulted in a reduction in size of all papillomas. Volumes of
wild type, E7/8, E7/14 and E7/18 papillomas were reduced 30–50%, and
volumes of E7/22 papillomas were reduced 75% (see Table 1). Figure
shows results for wild type (q,N), E7/18 (n,m) and E7/22 (%,&)
papillomas.
doi:10.1371/journal.pone.0002947.g009
Table 1. E7 immunization resulted in reduced papilloma size.
Genome % reduction in papilloma size by E7 immunization
week 8 week 11





Immunization of animals with wild type E7, followed by infection with wild type
and four codon-optimized genomes, resulted in reduction in size of papillomas.
Two time points (8 and 11 weeks) after infection are presented. The effect was
most notable with E7/22 for which a 75% reduction in size was measured.
doi:10.1371/journal.pone.0002947.t001
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that has been shown to greatly increase protein production in vitro.
We were concerned that the codon changes might interrupt
cryptic regulatory regions in the gene and so we built the genes
sequentially in order to be able to detect this possibility. We found
that the first two changes, E7/8 and E7/14, resulted in no obvious
phenotypic differences. The third change, E7/18, yielded a
somewhat enhanced growth rate and the fourth, E7/22, a
significantly reduced growth rate. The differences between the
E7/18 and E7/22 growth rates were highly significant (p,0 .001,
Student’s unpaired t test). We note that while our codon changes
were made at random, the end result was not random in that the
final changes (E7/18 and E7/22) were clustered in the 59 region of
the gene. We cannot rule out the possibility that the phenotypic
differences seen with these two genomes were the result of a special
sensitivity to change in this early region of the gene. This
possibility will be investigated in future experiments.
If protein expression increases with increasing numbers of
codon optimizations in E7, we might expect three possibilities. As
mentioned above, we might expect enhanced immune surveillance
and concomitant reduced growth. Alternatively, we might expect
increased growth due to enhanced activity of the oncogene. A
third possibility would be reduced growth rate due to excess E7
oncoprotein leading to increased apoptosis [43]. This apoptotic
effect could be due to either direct toxicity of the E7 protein or to
stimulation of cellular immunity which, in turn, would stimulate
apoptosis. All three mechanisms may counter-balance each other
in situ with growth being kept in check by immune control and/or
apoptosis, or enhanced by increased oncogenic activities. The data
in this paper would support this dynamic tension with E7/18
genomes demonstrating more oncogenic effects and E7/22
genomes inducing more immunological responses. These scenarios
are supported both by the growth data in the absence of
immunization and by the immunization study in which greatest
reduction of papilloma growth was observed in the E7/22
genome.
To our knowledge, this is the first in vivo study using codon-
altered papillomavirus genomes. We have shown phenotypic
differences in growth rates resulting from the changes as well as
differential responses to immunization. The work supports the
increasing body of evidence that synonymous codons are not
always silent and paves the way for further studies on codon
selection in E7 and other papillomavirus genes. We anticipate that
our model will be useful in helping to dissect the significance of
alternative codon usages.
Materials and Methods
Construction of codon-modified genomes
The Hershey CRPV progressive strain (H. CRPV) was used as
the backbone for all constructs. It was cloned into PUC 19 at
Sal1. The EcoRI site in the vector was removed and a Cla1 site
was introduced at 1383 just downstream of the E1 start. This
site, in conjunction with the naturally occurring EcoR1 site at
1063, was used to replace wild type E7 with codon-modified E7
genes.
Codon-modified E7 genes were created by site-directed
mutagenesis of wild type E7 cloned into PUC 19 at EcoR1
and BamH1. The E7 gene with BamH1 and EcoR1 ends was
obtained by PCR of the modified CRPV genome containing the
Cla1 site and this allowed for placement of modified E7 genes
into the wild type backbone. Codon changes were based on the
work of Zhou et. al. [2] and were done at random. Each
construct contained all mutations from the previous one; thus
E7/14 contained all the codon changes in E7/8 plus six more;
E7/18 contained those 14 codons plus 4 more, etc. Mutagenesis
was carried out using Pfu turbo (Stratagene, LaJolla, CA) and a
modification of the protocol for the Quick Change site directed
mutagenesis method in which the first round of amplification was
done with a single primer [35]. All mutations were verified by
DNA sequencing at the Core Facility of Pennsylvania State
University College of Medicine. Mutations are shown in Table 2
and Fig 1.
Construction of immunogen and expression constructs
Wild type CRPV E7 cloned into the VIJns expression vector
as previously reported was used as immunogen for DNA
vaccination [26]. VIJns empty vector was used as control. Wild
type CRPVE7, E7/8, E7/14, E7/18 and E7/22 were also
cloned into an expression vector PCR3 (Invitrogen) for testing of
in vitro expression. All constructs were confirmed by sequencing
in the Core facility of Pennsylvania State University College of
Medicine.
E7 detection by flow cytometry analysis
One mg of PCR3 containing wtE7, E7/8, E7/14, E7/18 or E7/
22 was co-transfected with 0.5 mg PCR3 containing EGFP into an
immortalized rabbit cell line (RI) cultured in a 6-well plate
(samples in duplicates). The cells were harvested 48 hrs after
transient transfection and examined for GFP and nuclear E7
expression. For GFP expression, the cells were fixed with 16PBS
Table 2. Codon changes were done at random and include
those for numerous amino acids spanning the entire E7 gene.
2 isoleucine ata.atc E7/18
5 threonine act.acc E7/18
6 proline cct.ccc E7/22
8 leucine ctt.ctg E7/18
9 serine agt.agc E7/22
13 leucine cta..ctg E7/14
16 threonine act.acc E7/14
20 leucine ctt.ctg E7/8
21 serine agt.agc E7/8
27 alanine gca.gcc E7/8
28 leucine tta.ctg E7/22
31 leucine tta.cta E7/14
31 leucine cta.ctg E7/22
32 serine agt.agc E7/14
40 glutamine caa.cag E7/18
51 alanine gca.gcc E7/8
61 glutamine caa.cag E7/14
62 threonine act.acc E7/14
74 isoleucine ata.atc E7/8
81 leucine cta.ctg E7/8
83 alanine gca.gcc E7/8
85 leucine ctt.ctg E7/8
The location (amino acid number within the E7 gene) and identity of all codon
changes is shown as well as the amino acids whose codons were changed.
Genomes were built sequentially. Thus, E7/14 contains all the changes in E7/8
plus 6 unique to itself. E7/18 contains all E7/14 changes plus 4 unique to itself.
E7/22 contains all of the previous changes plus 4 unique to itself.
doi:10.1371/journal.pone.0002947.t002
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cells were fixed with cytofix/cytoperm (BD) solution and
incubated with an in-house generated mouse anti CRPVE7
monoclonal antibody (SE7.1, 1:500) and subsequently with a PE-
conjugated anti-mouse IgG (1:50). The cells were then fixed with
2% PFA PBS for FSCAN test as previously described [36].
E7 detection by immunoprecipitation
Cells (1610
6) transiently transfected with the different E7
constructs were also harvested in 500 ml lysis buffer (RIPA:
50 mM Tris.HCl PH 7.5, 150 mM NaCl, 1% NP-40, 0.5%
Sodium Deoxycholride, 0.1% SDS) on ice for 30 minutes. The
cells were spun down (14,000 rpm, 10 minutes). 100 ml of the
supernatant was incubated with 5 ml of normal rabbit serum and
20 ml of sepharose A and rotated in the cold room (4uC) for
2 hours. The mixture was spun down again and the supernatant
was collected and incubated with 20 ml of sepharose A and mouse
anti-CRPVE7 MAb (1:1000) overnight in a cold room rocker. An
additional 30 ml of sepharose A was added the next day and
incubated for 2 more hours before the cells were spun down. The
pellets were collected and boiled with 40microliters protein
loading buffer for five minutes. The samples were analyzed via
western blot assay as previously described [37].
Northern blot analysis
RNAs were isolated from either transfected cells or papilloma
tissue using the Trizol reagent (Invitrogen, Carlsbad, CA). 5 mg
RNA from each sample (duplicates for each sample) was run out
on a 1% formaldehyde gel using reagents from the Ambion
Northern Max kit (Ambion, Austin, Texas). RNAs were blotted to
Hybond N
+ (Amersham, Piscataway, N.J.) using downward
transfer and were fixed to the membrane using the Stratalinker
1800(Stratagene, La Jolla, CA).
32P ATP probe was prepared from
a mixture of wild type and codon-modified DNAs using standard
Klenow labeling. Hybridization was carried out according to the
Ambion protocol. Membrane was exposed to Kodak X-OMAT
film (Rochester, NY). Densitometric analysis to determine relative
signals was done in the Core Facility at Penn State University
College of Medicine. Membranes were stripped following probing
with the labeled E7 DNA mixture and reprobed with beta actin as
a loading control.
Quantitative RT-PCR analysis of total RNA isolated from
cells transiently transfected with expression constructs of
wild type E7, E7/14, E7/18 and E7/22 and isolated at
different time points following treatment with
Actinomycin D
To evaluate mRNA copy number and mRNA stability and to look
at these parameters over time, we did QRT- PCR analysis on RNAs
extracted from cells that had been transiently transfected with E7
expression constructs and isolated at time points 0 hours, one hour,
1.5 hours, 2 hours, 4 hours and 6 hours following treatment with
Actinomycin D. RNAs were isolated using the TRIzol (Invitrogen)
reagent and were treated with Turbo-DNA-free (Ambion) to remove
any contaminating DNA; they were then quantitated spectrophoto-
metrically. Reverse transcription and quantitative PCR were
performed on 100 ng total RNA per reaction in the same closed
strip tubes using Stratagene’s Brilliant II QRT-PCR one step kit (#
600809). Primers and probe were designed using Primer Express
software
. TATA-binding protein (TBP) amplicons were generated
using primers 59 CACGGCACTGATTTTCAGTTCT 39 (nt 627–
648) and 59TTCTTGCTGCCAGTCTGGACT 39 (nt706–686) at
final concentrations of 200 nM` . Probe for TBP was fluorogenic
TaqMan probe 59HEX TGTGCACAGGAGCCAAGAGT-
GAAGA BHQ-1 39 and was used at a final concentration of
100 nM. CRPV E7/14, 18 and 22 primers were 59AAGCGCTG-
TAGGCAGACCA 39 (N 16–35) and 59TCGATTCAAGGTTCT-
GATGGC 39 (84–105) and were used at a final concentration of
300 nM. Probe was fluorogenic TaqMan probe 59FAM
CAGCTTCGTCTGCGTCTGTGATCCA-BHQ-1 39 (36–61)
and was at a final concentration of 100 nM. Wild type CRPV E7
primers were 59 CCATGTAAGCGCTGTAGGCAAA 39 (10–32)
and 59GCAGTCGATTCAAGGTTCTTATGGC 39 (85–109) and
were used at a final concentration of 300 nM. Probe was 59FAM
TCAGCTTCGTCTGCGTCTGTGATCC BHQ-1 39 (35–60) and
was used at a final concentration of 100 nM. Primers and probes for
the E7 genes were synthesized by Integrated DNA Technologies. A
standard curve was run on each plate using the appropriate E7
plasmid DNA as template at 1:2 dilutions. All QRT- PCR reactions
were performed using the Mx-4000 (Stratagene). Cycling conditions
were 50uC for 30 min (reverse transcription) followed by one cycle at
95uC to activate the polymerase, and then by 42 cycles of 94uCf o r
15 sec and 60uC for one min. Absolute quantities were determined
using the standard curve. Each transfection was carried out in
duplicate and RNAs from each time point for each E7 gene were run
in duplicate. Each gene required a separate run. No template (No
NT) controls were included on all plates and No reverse transcriptase
(No RT) reactions were run for all samples. Standard curve reactions
did not receive reverse transcriptase.
DNA vaccination of rabbits
New Zealand White (NZW) outbred rabbits were purchased
from Covance (Denver, PA) and maintained in the animal facility
of the Pennsylvania State University College of Medicine as
described above. The studies were approved by the Institutional
Animal Care and Use Committee of the Pennsylvania State
University. Inner ear skin sites were shaved and swabbed with
70% ethanol, and then DNA/gold particles were bombarded onto
these sites by a gene gun at 400 lb/in
2 [35]. Animals were
immunized with 10 shots (five per ear) of either wild type E7
expression construct or VIJns vector as control. This represents a
theoretical 10 mg. Immunizations were done at 2–3 week intervals.
A total of four immunizations were done rather than the normal
three as we encountered problems coating the DNA/gold onto the
tubing. One week after the final booster immunization, each
rabbit was challenged with 10 mg wt H. CRPV DNA and each of
the codon-optimized genomes, E7/8, E7/14, E7/18 and E7/22,
at two sites per construct using the protocol discussed below.
There were six animals per group.
DNA challenge and monitoring of tumors
The CRPV plasmids were purified by cesium chloride
ultracentrifugation and adjusted to 200 mg/ml in 16 TE buffer
[36] for challenge on animals. For application of viral DNA,
rabbits were sedated using Ketamine (40 mg/kg)/xylazine (5 mg/
kg) anesthesia. Back skin of the animals was scarified with a scalpel
blade to create an abrasion. Three days later, the wounded sites
were lightly scratched with a scalpel blade to introduce nicks into
the scabs. 10 micrograms of DNA in 50microliters of TE was
applied to each site and the DNA was worked into the wound with
a tuberculin syringe. [36]. Monitoring of papilloma outgrowth
began two weeks later and continued until week 12.
Statistics
Papilloma size was determined by calculating the cubic root
of the product of length6width6height of individual papillomas
in millimeters to obtain a geometric mean diameter (GMD). Data
Synonymous Codon Changes in E7
PLoS ONE | www.plosone.org 8 August 2008 | Volume 3 | Issue 8 | e2947were represented as the means6SEMs (standard errors) of
the GMDs for each test group. Statistical significance was
determined by unpaired t-test comparison (P,0.05 was considered
significant).
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